Newronika
Milan
About Newronika
Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $28.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2025)
- Website: newronika.com
- Phone: [email protected]
Industries & Categories
Bioinformatics, Biotechnology, Health Care, Medical Device, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/newronika-7278 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.